INDIA'S FIRST WEB PORTAL TO RAISE AWARENESS ABOUT SCOLIOSIS AND KYPHO-SCOLIOSIS
! STOP BENDING NOW !
Friday, 20 July 2018
Nuvasive Launches MAGEC X For Early Onset Scoliosis Treatment
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the U.S. launch of MAGEC X, a new procedural solution within the MAGEC product family that addresses Early Onset Scoliosis (EOS).
MAGEC X features updates across all rod diameters in the portfolio, including 5.0mm diameter rods for patients, delivering a 68 percent performance increase over the previous generation in titanium rod fatigue testing. When paired with the NuVasive Reline® Small Stature system, the first pediatric deformity fixation solution to integrate both 4.5mm and 5.0mm rods in a low-profile tulip, MAGEC X provides increased construct strength without sacrificing the optimal profile for EOS patients.
"NuVasive's MAGEC X 5.0mm solution is unique because it allows you to upsize your rod with low-profile screws, giving you the flexibility at the time of surgery to use a larger rod without having to change your screws – that's really key," said Dr. Peter Sturm, Alvin H. Crawford Chair of Spine Surgery, Cincinnati Children's Hospital Medical Center. "Further, the upgrade of the internal components in MAGEC X rods gives me even more confidence in the performance of a system that has radically changed how we treat this challenging patient population."
The development of MAGEC X is also distinguished by a number of internal rod mechanism advancements, most notably a reinforced locking pin and a robust actuator seal designed to further contain and reduce the release of titanium wear debris. Additionally, it includes an anti-jam feature to simplify intraoperative and postoperative rod lengthening. Key aesthetic improvements, such as laser-marked sagittal bending lines, help to enhance surgeon workflow efficiency and ease of use.
"More than 100,000 children are diagnosed with scoliosis each year in the United States; the launch of MAGEC X exemplifies our continued dedication to the advancement of EOS treatment and support of the pediatric surgeon community," said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. "MAGEC X represents the culmination of over a decade of clinical experience and innovation, resulting in a stronger and smarter MAGEC implant design."
This full commercial launch of MAGEC X follows the Company's preview announcement, which occurred at the POSNA Annual Meeting in May in Austin, Texas.
About NuVasive NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
Forward-Looking Statements NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.